Awardees of the CF AMR Syndicate’s Collaborative Discovery Programme had the unique opportunity to receive feedback on their innovations from people with cystic fibrosis
Earlier this year, six early-stage drug discovery organisations, funded by the CF AMR Syndicate’s Collaborative Discovery Programme (CDP), had the opportunity to share their innovations with people living with cystic fibrosis (CF) and their loved ones in a live, online Dragon’s Den-style event.
The CF AMR Syndicate’s CDP is advancing an exciting and diverse pipeline of preclinical projects for CF lung infections.
The organisations in the programme were invited to pitch their innovations to a panel of members of the CF community. They shared information about the projects’ aims and the progress they are each making in developing their therapeutics.
The event was facilitated by Cystic Fibrosis Trust’s Involvement team and members of the CF AMR Syndicate. It offered a unique opportunity for the CDP awardees to receive feedback on their innovative products in development. Since the CF community was involved in the selection of projects entering the CDP, the event also provided an opportunity for them to hear firsthand how the projects are progressing, as well as to provide additional feedback to shape the projects further.
Comments and questions from the panel ranged from the practicalities of fitting proposed dosing regimens around day-to-day working lives to concerns about the effectiveness and side effects of the products, as well as preferences for methods of drug administration.
“It was a fantastic opportunity for members of our involvement group to contribute to the successful translation of these early-stage projects. They welcomed the approaches and novel mechanisms being explored. From shortening lengthy treatment durations to minimising side effects and drug interactions, especially with CFTR modulators.” commented Lorna Allen, Involvement Manager at Cystic Fibrosis Trust.
The Syndicate’s CDP offers a unique collaborative approach to project development and delivery. In addition to funding, our awardees benefit from additional collaborative support aligned with the unmet needs identified in our Therapeutic Target Product Profiles for cystic fibrosis lung infections to help increase the probability of success.
Support through the early development phases to generate essential data packages will position these projects to attract onward funding and investment for further development.
Click here to find out more about the organisations and their innovations in development.
